SCHEMBL2908004

SCHEMBL2908004

Nc1ncnc2n[nH]c(C#CCCO)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 16/20 0.41
PIK3CA P42336 16/20 0.41
PIK3CB P42338 16/20 0.41
PIK3CG P48736 16/20 0.41
PRKDC P78527 16/20 0.41
ABL1 P00519 4/20 0.40
SRC P12931 4/20 0.40
MTOR P42345 3/20 0.38
EGFR P00533 3/20 0.38
HCK P08631 2/20 0.38
KDR P35968 2/20 0.38
EPHB4 P54760 2/20 0.38
PI4KB Q9UBF8 2/20 0.38
SGK1 O00141 1/20 0.37
MEN1 O00255 1/20 0.37
DYRK3 O43781 1/20 0.37
EIF4E P06730 1/20 0.37
EIF2AK2 P19525 1/20 0.37
CSNK1D P48730 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL887825 0.88 PIK3CD (0.43) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL887847 0.84 PIK3CD (0.44) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL2908006 0.78 TLR7 (0.35) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL2909210 0.78 ABL1 (0.33) ABL1SRCEGFRMKNK1MKNK2
SCHEMBL887795 0.77 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL8323143 0.77 PIK3CD (0.49) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL2910181 0.71
SCHEMBL11344478 0.69 PIK3CD (0.48) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL3420175 0.66 PIK3CD (0.59) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL8325669 0.65 PIK3CD (0.46) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7715989-B2 Systems and methods for predicting oligonucleotide melting temperature (TmS) ELITECH HOLDING B.V. (NL) 2010-05-11 US claimed
US-7553643-B2 Method for amplifying target nucleic acid sequences using a primer comprising an AP endonuclease-cleavable linker EPOCH BIOSCIENCES, INC. (US) 2009-06-30 US claimed
EP-1430147-B1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES INC (US) 2013-05-22 EP disclosed
EP-1975256-B1 Modified oligonucleotides for mismatch discrimination EPOCH BIOSCIENCES INC (US) 2012-07-11 EP disclosed
EP-1261616-B1 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION EPOCH BIOSCIENCES INC (US) 2010-08-18 EP disclosed
US-7751982-B2 TM leveling methods ELITECH HOLDING B.V. (NL) 2010-07-06 US disclosed
US-7715989-B2 Systems and methods for predicting oligonucleotide melting temperature (TmS) ELITECH HOLDING B.V. (NL) 2010-05-11 US disclosed
EP-1995330-A1 Modified oligonucleotides for mismatch discrimination Epoch Biosciences, Inc. (US) 2008-11-26 EP disclosed
EP-1975256-A1 Modified oligonucleotides for mismatch discrimination Epoch Biosciences, Inc. (US) 2008-10-01 EP disclosed
EP-1944310-A2 Modified oligonucleotides for mismatch discrimination Epoch Biosciences, Inc. (US) 2008-07-16 EP disclosed
EP-1537488-A4 SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) EPOCH BIOSCIENCES INC (US) 2008-07-02 EP disclosed
EP-1430147-A1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS Epoch Biosciences, Inc. (US) 2004-06-23 EP disclosed
WO-2002099141-A9 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES INC (US) 2004-05-27 WO disclosed
US-6683173-B2 CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER EPOCH BIOSCIENCES, INC. 2004-01-27 US disclosed
US-20030235822-A1 Systems and methods for predicting oligonucleotide melting temperature (TmS) EPOCH BIOSCIENCES, INC. 2003-12-25 US disclosed
WO-2003107144-A2 SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) EPOCH BIOSCIENCES, INC. (US) 2003-12-24 WO disclosed
US-20030224359-A1 TMLEVELING METHODS EPOCH BIOSCIENCES, INC. 2003-12-04 US disclosed
WO-2002099141-A1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES, INC. (US) 2002-12-12 WO disclosed
EP-1261616-A2 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION Epoch Biosciences, Inc. (US) 2002-12-04 EP disclosed
WO-2001064958-A2 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION EPOCH BIOSCIENECS, INC. (US) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030224359-A1 TMLEVELING METHODS PTBP3, RNGTT, DTYMK PIK3CD 4726/4885PIK3CA 3455/4885PIK3CB 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.